| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GDC-0941 | CTRPv2 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | AKT inhibitor VIII | GDSC1000 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | Bosutinib | FIMM | pan-cancer | AAC | -0.55 | 0.3 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | 0.034 | 0.3 |
| mRNA | MG-132 | CTRPv2 | pan-cancer | AAC | 0.064 | 0.3 |
| mRNA | ML083 | CTRPv2 | pan-cancer | AAC | -0.042 | 0.3 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | 0.05 | 0.3 |
| mRNA | SNX-2112 | CTRPv2 | pan-cancer | AAC | 0.034 | 0.3 |
| mRNA | KIN001-135 | GDSC1000 | pan-cancer | AAC | 0.058 | 0.3 |